The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.
Radiology is one of the branch of Medical Science that works on Medical imaging.
Radiology is divided into two sub-fields, diagnostic radiology and therapeutic radiology.
Diagnostic radiology uses various imaging modalities in the diagnosis of disease. In all the medical care fields’ diagnostic radiology plays important role in disease diagnosis.
Commonly used imaging modalities are:
In Vitro Diagnostics (IVD) are the medical devices, accessories, instruments, reagents and systems deployed to perform medical test on samples (e.g., blood, urine and tissue taken from human body) to diagnose diseases, detects infections, diagnose medical conditions, monitor drug therapies, prevent diseases. Some tests usually performed in authorized laboratories by the trained healthcare professionals and some tests can be done at home. Devices may range from simple tests to sophisticated DNA technology including calibrators, control materials, kits, reagents, software, or related instruments. IVD is an important segment in the global healthcare industry. The marketplace is witnessed rapid growth supported by advancements in technologies, evolvement of new tools, improvement in disease monitoring, higher demand of OTC tests, increased prevalence of infectious and other diseases like oncology, cardiovascular etc. IVD products are classified into Class I, III and III by FDA regulations to assure their safety and effectiveness.
- Track 2-1: infectious Disease testing options: Respiratory Diseases, Gastrointestinal Diseases, and Bloodstream Infections etc.
- Track 2-2: Molecular Genetics in diagnosis of haematological malignancies
- Track 2-3: Screening, Prevention, Early detection: Cancer, Infectious diseases, healthcare-associated infections (HAI), Antimicrobial resistance (AMR), Diabetes, Genetic diseases, and Rare diseases
- Track 2-4: Diagnosis: Diabetes, Sexually Transmitted Diseases (STDs), Infectious diseases, Cholesterol, Heart Disease, Pregnancy, Allergy, Immunology Renal disease
- Track 2-5: Prognosis: Cancer, HIV, Heart disease Immunology, and Sepsis
- Track 2-6Monitor Treatment Performances: Diabetes, Anticoagulation, Antibiotics, and Viral load
Point-of-care testing (POCT) are the medical tests that are performed by trained healthcare professionals at or near the site of patient. Main POCTs include blood and urine tests. POCT is aimed to collect specimen and get accurate results in a very short span of time. POCTs are mainly used in primary care, secondary care and community care based settings. POCT are performed via portable instruments such as blood glucose meter, blood gas, pH, electrolyte and metabolite and haemoglobin measurement meters.
A companion diagnostic is a medical device/ diagnostic test/ imaging tool, used companion to drugs and provides information regarding the applicability of drug or biologics to a specific person. It helps the healthcare professionals to determine whether the product will be beneficial to the patients or will have any risks or side effects.
Molecular Diagnostics is a collection of various techniques that are used to analyse biological markers in the proteome and genome and how their cells expressed the genes by the application of molecular biology to genetic testing. Globally the use of Molecular diagnostics growing rapidly. Major clinical applications are in the areas of oncology, infectious disease, genetic diseases, pharmacogenomics, human leukocyte antigen typing; and coagulation.
Last five decades has seen a tremendous growth in Immunodiagnostics tests and it emerged as a potential diagnostic technique. The radioimmunoassay and Enzyme Linked Immunosorbent Assay (ELISA) were the predominant techniques during the initial era of Imunodiagnostics.
- Track 3-1: Current trends, Future Market, Issues & Challenges:
- Track 3-2: Point of Care Diagnostics (POCs)
- Track 3-3: Companion Diagnostics
- Track 3-4: Molecular Diagnostics
- Track 3-5: Immunodiagnostics
- Track 3-6: Hematological Diagnosis
- Track 3-7: Clinical Chemistry
- Track 3-8: Microbial Applications
In vitro fertilization (IVF) treatment is mind boggling arrangement of methodology utilized for richness treatment or hereditary issues and help with the origination of a youngster. Amid in vitro preparation, develop eggs were gathered from ovaries and treated by sperm in a lab conditions. In vitro treatment is the best type of helped regenerative innovation. Amid in vitro preparation, eggs and sperm are united in research facility glass dish to enable the sperm to treat an egg. Utilizing as a part of vitro preparation, one can utilize any mix like claim eggs and sperm or giver eggs and sperm. After in vitro preparation, at least one treated eggs are put in the uterus.
Noninvasive prenatal testing (NIPT), Liquid biopsy, Next-generation sequencing (NGS), and circulating tumor cell (CTC) tests etc. are considered as the future of the In Vitro Diagnostics (IVD). These areas of the IVD market is expected to witness a rapid growth in coming few years. In coming five years, the cost of NGS test will rise from $250 million to $800 million with the total number of NGS sales only rise from 100 million to 300 million. Though globally, the growth of IVD market is stagnant, it is predicted that NIPT will grow at a rate of 20% in USA and even more in abroad. Other future IVD devices include point of care biochemistry analyser (eg. Abbott i-STAT) blood gas analyser (eg. biosurfit spinit), immunology, haematology, and clinical chemistry analyser (eg. Acon Blood Glucose, Total Cholesterol, Cholesterol 3-1, Haemoglobin Meters and Hemoccult), and FOB test.
- Track 5-1: Microarray technology
- Track 5-2: Noninvasive prenatal testing (NIPT)
- Track 5-3: Next-generation sequencing (NGS)
- Track 5-4: Liquid biopsy
- Track 5-5: Circulating tumor cell (CTC) tests
- Track 5-6: High value-added polymerase chain reaction (PCR), Digital PCRs & Q-PCRs
- Track 5-7: Point of care biochemistry analyser
- Track 5-8: Blood gas analyser, Total Cholesterol, blood glucose and Haemoglobin Meters
- Track 5-9: Immunology and clinical chemistry analysers
- Track 5-10: Sepsis markers, Stroke markers and DNA testing
The US Food and Drug Administration (FDA) is involved in the regulation of IVDs or laboratory tests after the inception of the Medical Device Amendments of 1976. According to the guidelines of the FDA, IVD products are classified into Class I, II, or III which is based on the level of regulatory control that is essential to ensure the safety and effectiveness of devices. The Code of Federal Regulations lists the classification of existing IVDs in 21 CFR 862, 21 CFR 864, and 21 CFR 866. CLIA '88 is responsible for the quality standards of laboratory testing and an accreditation program for clinical laboratories. In the EU market, the In Vitro Diagnostics Directive (IVDD) 98/79/EC is the main regulatory requirements that medical device manufacturers comply with to get a CE marking in their products.
- Track 6-1: IVD regulations in the USA, EU, Asia and Middle East
- Track 6-2: Updated ISO 13485:2016 towards the QMS requirements of IVDR
- Track 6-3: Compliance issues with Post Market Surveillance
- Track 6-4: POCT policy and Reporting Issues
- Track 6-5: Classifications of IVD & Requirements of IVD labelling
- Track 6-6: Good Manufacturing Practices (GMPs) , Quality System Regulations (QSRs) and Medical Device Listing
- Track 6-7: European requirements for CE marking
As one of the fastest-growing areas of In vitro diagnostics, Oncology testing to become an $8 billion market in 2018. It is not surprising that the most strenuous efforts in medical science are aimed at the no.2 killer disease. Oncology killed more than 7 million people worldwide in 2010, which is more than AIDS, massslaria, and tuberculosis combined. It is second heart leading disease-causing death across the globe. Annual Oncology deaths would reach13.2 million by 2030.An important step in oncology testing is digital imaging that eliminated human stained-tissue slide reading.
- Track 7-1: Molecular Diagnostic Tests of Cancer Diagnosis: Sequencing in Cancer Testing, Tissue Function Tests, PSA, CEA and Other Immunoassays, Flow Cytometry, Pap and HPV Testing, FOB and Other Rapid Tests, Molecular Oncology Assays, Tissue Microarrays, Methylat
- Track 7-2: Early Diagnosis and Treatment of Cancer
- Track 7-3: Application and role of NGS in Cancer Diagnosis
- Track 7-4: Liquid biopsy in cancer detection, diagnosis and monitoring
- Track 7-5: Proteomic technologies for early detection of cancer
- Track 7-6: Circulating Tumour Cells (CTC) in cancer predication
- Track 7-7: Precision Medicines for Oncology
Infectious diseases are disorders that are caused by various organisms like bacteria, viruses, fungi or parasites. They are transmitted through contaminated foods and through physical contacts. Infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), Herpes Simplex Virus (HSV), tuberculosis, measles, dengue, Chagas, cholera, and malaria are increasing across the globe, mostly in developing countries.
In Vitro Diagnostics (IVDs) help in identifying the pathogenic agent such as bacteria, viruses or fungi that are responsible infectious diseases and alo helps to select the appropriate treatment options. Molecular Diagnostics Tests also helps to perform both targeted and syndromic Clinical Tests for Infectious Diseases resulting the incresing demands.
As per a research it is found that the Global IVD Infectious Disease market is anticipated to hit $25.9bn by end of the year 2022. Major drivers of the IVD market for the Infectious Disease are launch of new advanced Diagnostics Devices, rapid growth of infectious disease, accuracy and cost effectiveness of the Diagnostics Devices etc.
- Track 8-1: Molecular Diagnostics Testing
- Track 8-2: Molecular Diagnostics in Infectious disease
- Track 8-3: Anti-microbial resistance (AMR) and Point of Care Testing (POCT)
- Track 8-4: Rapid diagnosis in acute care: influenza, pneumonia etc.
- Track 8-5: Diagnostic monitoring of adenovirus infections
- Track 8-6: Point of care testing (POCT) for infectious diseases
- Track 8-7: PCR assays in diagnosing Multi Drug Resistant (MDR) pathogens
Cardiovascular ailment (CVD) is a class of infections that include the heart or veins. Cardiovascular sickness incorporates coronary corridor infections (CAD, for example, angina and myocardial dead tissue (usually known as a heart assault). Different CVDs incorporate stroke, heart disappointment, hypertensive coronary illness, rheumatic coronary illness, cardiomyopathy, heart arrhythmia, inherent coronary illness, valvular coronary illness, caritas, aortic aneurysms, fringe corridor sickness, thromboembolic infection, and venous thrombosis.
Diabetes, is likewise knows as diabetes mellitus, is a gathering of metabolic issue where high glucose levels over a drawn-out period found. Side effects of high glucose incorporate regular pee, expanded thirst, and expanded appetite. They are two sorts of diabetes: Type1DM, comes about because of insulin inadequacy, and Type2DM, comes about because of insulin protection and gestational diabetes that outcomes from pregnant ladies with medicinal history of diabetes.
Traditional biosensors like glucose meters and glycohemoglobin test kits are commonly used for In Vitro Diagnosis of the disease and long-term management of diabetes. The increasing prevalence of diabetes and the demand for the diagnostic tests helps to drive the market and to go for new R&D in this sector to develop innovative products.Other Point of Care Tests such as HbA1c are preferred due to their capability of Rapid Diagnosis and management of diabetes with a reduced cost.
- Track 9-1: Cardic Markers for in diagnosis and monitoring
- Track 9-2; Cardiac Biomarkers: CK-MB, Troponin, Myoglobin, Myeloperoxidase (MPO), Brain natriuretic peptide (BNP), proBNP, high sensitive Creactive protein (hsCRP), homocysteine, Fatty Acid Binding Protein (FABP), Glycogen Phosphorylase isoenzyme BB (GPBB), urinar
- Track 9-3: Point-of-Care (POC) test in cardiovascular diseases
- Track 9-4: Diagnostic screening using IVD and diagnostic imaging technologies
- Track 9-5: Challenges in Diagnosis improvement
- Track 9-6: Future of Cardiovascular Diagnostics
Nephrology is a claimed to fame of pharmaceutical and paediatrics that frets about the kidneys: the investigation of ordinary kidney capacity and kidney issues, the conservation of kidney wellbeing, and the treatment of kidney issues, from eating routine and medicine to renal substitution treatment (dialysis and kidney transplantation). Fundamental conditions that influence the kidneys, (for example, diabetes and immune system malady) and foundational issues that happen in view of kidney issues, (for example, renal osteodystrophy and hypertension) are additionally examined in nephrology. A doctor who has attempted extra preparing to wind up plainly a specialist in nephrology may call themselves a nephrologist or renal doctor. IVD methodologies help in rapid diagnostics of Nephrological disorders and shown a new avenue.
- Track 10-1: Diagnostic tests to detect renal function
- Track 10-2: Renal Biomarkers
- Track 10-3: Next-generation sequencing (NGS) in diagnostics of kidney disease
An IVD Medical Device defined as a device which, whether used alone or in combination for the in-vitro examination of specimens derived from the human body solely or principally to give information for diagnostic, monitoring or compatibility purposes. Biomarkers can be a substance used for examining organ function and condition. There are two major types of biomarkers: biomarkers of exposure, that are used in risk prediction, and biomarkers of disease, that are used in screening, diagnosis and monitoring of disease progression. Additional potential of molecular biomarkers is to identify individuals susceptible to disease. Examples of Biomarkers body temperature for fever, cholesterol for heart stroke, C-reactive protein for inflammation.
- Track 11-1: Roles of Biomarkers in IVD
- Track 11-2: Challenges in new marker & technologies
- Track 11-3: Role of Biomarkers in personalized treatment of Cancer
- Track 11-4: Biomarkers in Early Cancer Diagnosis
- Track 11-5: Role of Prognostic biomarkers
- Track 11-6: Diagnostic Biomarkers in cancer, liver dysfunction, infectious diseases, diabetic nephropathy, renal function, nephrotoxicity etc.
An Immunoassay is a biochemical test that measures the nearness or convergence of a macromolecule or a little particle in a solution using a counter acting agent (for the most part) or an antigen (some of the time). The particle identified by the Immunoassay is frequently alluded to as an "analyte" and is much of the time a protein, although it might be different sorts of atoms, of various size and sorts, if the best possible antibodies that have the sufficient properties for the test are created. Analytes in organic fluids, for example, serum or pee are oftentimes measured utilizing Immunoassays for restorative and research purposes. In vitro diagnostics which test an example of tissue or organic liquids, for example,
Microbiological culture, which decides the nearness or non-appearance of organisms in a specimen from the body, for the most part focused at recognizing pathogenic microorganisms. For example; Genetic testing, Blood Glucose, Liver Function Tests, Calcium test, Electrolytes in the blood, for example, Sodium, Potassium, Creatinine, and Urea.
- Track 12-1: Immunoassays for IVD: ELISA, Multiplex assays, SELDI, LC/MS, Microarrays, Enzyme multiplied immunoassay technique (EMIT)Turbidimetric assays, Paramagnetic particle based assay, Chemi- Luminescent Immunoassay (CLIA), EIA, Fluorescent immunoassay (FIA), R
- Track 12-2: Second generation Multiplex Immunoassays
- Track 12-3: Automation of Multiplex Assays for Clinical Diagnosis
- Track 12-4: Microfluidics and Polymer Lab-on-a-Chips
- Track 12-5: High-Sensitivity Immunoassays for IVD Applications
- Track 12-6: Errors reduction in Immunoassay Testing
- Track 12-7: Nanoparticles-Based Naked-Eye Colorimetric Immunoassays for In Vitro Diagnostics